

PD1 pathway in immune-mediated myopathies

Pathogenesis of dysfunctional T cells revisited

Samuel Knauss, MD, Corinna Preusse, PhD, Yves Allenbach, MD, PhD, Sarah Leonard-Louis, MD, Mehdi Touat, MD, Norina Fischer, Helena Radbruch, MD, Ronja Mothes, Vitali Matyash, PhD, Wolfgang Böhmerle, MD, Matthias Endres, MD, Hans-Hilmar Goebel, MD, Olivier Benveniste, MD, PhD, and Werner Stenzel, MD

Correspondence

Dr. Stenzel
werner.stenzel@charite.de

Neurol Neuroimmunol Neuroinflamm 2019;6:e558. doi:10.1212/NXI.0000000000000558

Abstract

Objective

To investigate the relevance of dysfunctional T cells in immune-mediated myopathies. We analyzed T-cell exhaustion and senescence, in the context of programmed cell death protein 1 (PD1)-related immunity in skeletal muscle biopsies from patients with immune-mediated necrotizing myopathy (IMNM), sporadic inclusion body myositis (sIBM), and myositis induced by immune checkpoint inhibitors (irMyositis).

Methods

Skeletal muscle biopsies from 12 patients with IMNM, 7 patients with sIBM, and 8 patients with irMyositis were analyzed by immunostaining and immunofluorescence as well as by quantitative PCR. Eight biopsies from nondisease participants served as controls.

Results

CD3⁺CD8⁺ T cells in biopsies from IMNM, sIBM, and irMyositis were largely PD1-positive, while CD68⁺ macrophages were sparsely positive to the ligand of programmed cell death protein 1 (PD-L1). The sarcolemma of myofibers was PD-L2⁺ and was colocalized with major histocompatibility complex (MHC) class I. CD68⁺ macrophages were colocalized with PD-L2. Senescent T cells were strongly enriched in skeletal muscle of sIBM, revealing a distinct immunologic signature. Biopsies from patients with irMyositis showed mild signs of senescence and exhaustion.

Conclusion

Persistent exposure to antigens in IMNMs and sIBM may lead to T-cell exhaustion, a process controlled by the PD1 receptor and its cognate ligands PD-L1/PD-L2. To our knowledge, these data are the first evidence of presence of dysfunctional T cells and relevance of the PD1 pathway in IMNM, sIBM, and irMyositis. These findings may guide the way to a novel understanding of the immune pathogenesis of immune-mediated myopathies.

From the Department of Neurology (S.K., W.B., M.E.) and Department of Neuropathology (C.P., N.F., H.R., R.M., V.M., H.-H.G., W.S.), Charité—Universitätsmedizin, Berlin, Germany; Department of Internal Medicine and Clinical Immunology (Y.A., O.B.), Assistance Public-Hôpitaux de Paris, Sorbonne-Université, INSERM, UMR974, Pitié-Salpêtrière University Hospital; Unité de Pathologie Neuromusculaire (S.L.-L.), Centre de Référence Paris-Est, Groupe Hospitalier Pitié-Salpêtrière; Service de Neurologie 2-Mazarin (M.T.), Hôpitaux Universitaires La Pitié Salpêtrière—Charles Foix, APHP; OncoNeuroTox Group (M.T.), Center for Patients with Neurological Complications of Oncologic Treatments, Hôpitaux Universitaires Pitié-Salpêtrière—Charles Foix et Hôpital Percy; Inserm U 1127 (M.T.), CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM, Université Pierre-et-Marie-Curie, Sorbonne Université, Paris, France; Leibniz ScienceCampus Chronic Inflammation (H.R., R.M., W.S.); Center for Stroke Research Berlin (M.E.), Charité—Universitätsmedizin, Berlin; German Centre for Cardiovascular Research (DZHK) (M.E.); and German Center for Neurodegenerative Diseases (DZNE) (M.E.).

Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at [Neurology.org/NN](https://neurology.org/NN).

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Glossary

CTL = cytotoxic T cell; **HMGCR** = 3-hydroxy-3-methylglutaryl-coenzyme A reductase; **ICI** = immune checkpoint inhibitors; **IMNM** = immune mediated necrotizing myopathy; **IFN γ** = gamma interferon; **irMyositis** = myositis induced by immune checkpoint inhibitors. **MHC** = major histocompatibility complex; **mRNA** = messenger ribonuclein acid; **MSA** = myositis-specific antibody; **PD1** = programmed cell death protein 1; **PD-L1/2** = ligand of programmed cell death protein 1/2; **qPCR** = quantitative PCR; **sIBM** = sporadic Inclusion body myositis; **SRP** = signal recognition particle.

Autoantibodies against signal recognition particle (SRP) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) play a crucial role in the pathogenesis of immune-mediated necrotizing myopathies (IMNMs).^{1,2} Levels of autoantibody titres are directly linked to disease activity, and treatment response can be monitored by measuring the levels of autoantibodies in both anti-SRP- and anti-HMGCR-associated necrotizing myopathies.³ Antigens to these antibodies persist over a long time in the human body and stimulate the immune system in a specific way. In contrast to sporadic inclusion body myositis (sIBM), which is characterized by the presence of cytotoxic granzyme B⁺ and/or perforin⁺ T cells,⁴ IMNM is a paucilymphocytic disease. We have recently highlighted the presence of T cells in all examined IMNM biopsies; however, we showed that in IMNM, T cells lack robust cytotoxicity.¹ As opposed to IMNM, the specificity of an autoantibody (cN1A) in sIBM is less clear.^{5–7} Hence, persistence of antigens in IMNM may affect the phenotype of T cells in this disease. Indeed, T cells, exposed to persistent antigen and inflammatory molecules, may functionally deteriorate, a process called T-cell exhaustion.⁸ Exhausted T cells are subject to complex negative regulation involving signaling through multiple receptors that inhibit functional and proliferative responses, which in turn result in ineffective control of the inflammation.⁹ The CD28 family member programmed cell death protein 1 (PD1) is the most highly expressed inhibitory receptor on CD8⁺ T cells during chronic inflammation, and this receptor has a major role in regulating T-cell exhaustion. The role of PD1 expression in healthy adult humans to distinguish between effector T cells and exhausted T cells as well as the interpretation of increased expression levels of PD1 in infection as a single marker of exhaustion, however, has been much debated.^{10,11} Interestingly, PD1 has been shown to be upregulated early after T-cell activation and is not exclusively associated with states of T-cell dysfunction.¹² Importantly, blockade of the PD1 signaling pathway can restore appropriate antigen-specific T-cell responses in chronic infection and in the tumor environment.⁸ Immune checkpoint inhibitors (ICIs) successfully lead to tumor immune rejection in certain cancers by reactivating tumor response in exhausted T cells.¹³ However, therapy with these agents causes increased autoimmune responses with development of adverse effects including myositis and myocarditis.¹⁴ Exhaustion, anergy, and senescence are common concepts to describe dysfunctional states of T cells associated with increased expression of immune checkpoints, which may harbor overlapping, yet distinctive features, one of which is expression of CD57—low in exhaustion, but high in senescence.^{9,15,16} Senescent T cells enter a terminal

differentiation state owing to excessive cell replication, a process that is associated with irreversible cell cycle arrest and telomere shortening. CD57⁺ T cells have been studied in sIBM.¹⁷

In this study, we hypothesized that persistent antigen presentation in immune-mediated myopathies leads to dysfunctional states of invading T cells. This finding would provide further evidence for a direct recognition of muscular antigens by invading T cells, and a role for T cells in the pathogenesis of these diseases. In addition, we analyzed molecules driving T-cell exhaustion and senescence in skeletal muscle biopsies from IMNM with anti-SRP or anti-HMGCR antibodies and sIBM as well as ICI-associated immune toxicity-related myositis induced by immune checkpoint inhibitors (irMyositis).

Methods

Patients

Clinical data of all patients enrolled in this study are listed in the table. We included patients with clinical, serologic, and morphologic signs and symptoms consistent with IMNM¹⁸ and sIBM according to present criteria,¹⁹ as well as patients treated with ICIs suffering from ICI-induced myositis.

Standard protocol approvals, registrations, and patient consents

Informed consent was obtained from all patients at each institution involved. The Charité Ethics Committee (EA2/163/17), the French Ministry of Research, as well as the Research Ethics Committee of the Pitié-Salpêtrière Hospital (Paris, France) (AC 2008-87) granted ethical approval.

Skeletal muscle specimens

We analyzed skeletal muscle biopsies from 12 patients diagnosed with IMNM according to the clinico-sero-morphologic European Neuromuscular Centre criteria.¹⁸ Also, skeletal muscle biopsies from 7 patients with sIBM were included (clinically and morphologically definite sIBM)¹⁹ and 9 patients with myositis as an adverse event after ICI treatment according to recent data.²⁰ In addition, we investigated control skeletal muscle biopsies (n = 8) from patients with nonspecific myalgia, in whom muscle weakness and morphologic abnormalities in skeletal muscle biopsies were absent; creatine kinase levels were normal; no signs of systemic inflammation and no myositis-specific antibodies (MSAs) or myositis-associated antibodies had been detected. All skeletal muscle specimens had been cryopreserved at –80°C prior to analysis.

Table Characteristics of all patients included in the study

Patient number	Age	Sex	Duration of disease (mo)	Distribution of weakness	Antibody	Disease
IMNM1	54	M	4	Proximal tetraparesis	SRP	IMNM
IMNM2	35	M	4	Proximal paraparesis (UL)	SRP	IMNM
IMNM3	20	F	9	Proximal tetraparesis	SRP	IMNM
IMNM4	18	F	67	Proximal tetraparesis	SRP	IMNM
IMNM5	41	F	2	Proximal tetraparesis	SRP	IMNM
IMNM6	45	M	15	Proximal tetraparesis	SRP	IMNM
IMNM7	80	M	3	Proximal tetraparesis	HMGCR	IMNM
IMNM8	80	M	3	Proximal tetraparesis	HMGCR	IMNM
IMNM9	18	F	24	Proximal tetraparesis	HMGCR	IMNM
IMNM10	61	M	9	Proximal tetraparesis	HMGCR	IMNM
IMNM11	74	M	1	Proximal tetraparesis	HMGCR	IMNM
IMNM12	43	F	15	Proximal tetraparesis	SRP	IMNM
sIBM1	73	M	36	Proximal paraparesis (LL)		sIBM
sIBM2	72	M	N/A	Proximal paraparesis (LL)		sIBM
sIBM3	64	M	24	Tetraparesis and LFFw		sIBM
sIBM4	75	M	18	Proximal paraparesis (LL)		sIBM
sIBM5	72	M	36	Proximal paraparesis (LL)		sIBM
sIBM6	72	F	84	Tetraparesis and LFFw		sIBM
sIBM7	66	M	120	Tetraparesis and LFFw		sIBM
irM1	75	M	5 wk	Myocarditis, limb-girdle and axial weakness, ptosis, ophthalmoparesis		irMyositis
irM2	66	M	4 wk	Myocarditis, limb-girdle and axial weakness, ptosis, ophthalmoparesis		irMyositis
irM3	87	F	25 wk	Limb-girdle and axial weakness		irMyositis
irM4	75	M	73 wk	Limb-girdle and axial weakness		irMyositis
irM5	64	F	30 wk	Myocarditis, proximal tetraparesis		irMyositis
irM6	74	M	18 wk	Limb-girdle and axial weakness, ptosis, ophthalmoparesis		irMyositis
irM7	61	M	16 wk	Limb-girdle and axial weakness, ptosis, ophthalmoparesis		irMyositis
irM8	56	M	87 wk	Limb-girdle and axial weakness		irMyositis
irM9	84	M	56 wk	Limb-girdle and axial weakness		irMyositis
NC1	43	M				Control
NC2	2	M				Control
NC3	13	M				Control
NC4	17	F				Control
NC5	30	M				Control
NC6	49	F				Control
NC7	43	M				Control
NC8	47	M				Control

Abbreviations: HMGCR = hydroxy-3-methylglutaryl-coenzyme A reductase; IMNM = immune-mediated necrotizing myopathy; irMyositis = myositis induced by immune checkpoint inhibitors; LFFw = long finger flexor weakness; LL = lower limbs; sIBM = sporadic inclusion body myositis; SRP = signal recognition particle; UL = upper limbs.

Morphologic analysis

All stains were performed on 7 μ m cryomicrotome sections, according to standard procedures. Immunohistochemical and double immunofluorescence stains were obtained as described previously.²¹ The following antibodies were used for staining procedures: (primary antibody, dilution, company/clone): mouse anti-human CD3, 1:50, Dako/UCHT1; mouse anti-human CD68, 1:100 Dako/EBM1; MHCI, 1:1,000, Dako/w6/32; PD1, 1:100, Abcam/NAT105; PDL1, 1:100, Cell signalling/E1L3N; PDL2, 1:100, Abcam/Ty25.

RNA extraction and PCR

Total RNA extraction from muscle specimens and quantitative reverse transcription PCR were performed as described previously.²¹

cDNA was synthesized using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). For quantitative PCR (qPCR) reactions, 2 ng of cDNA were used, and for analysis, the 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) was used, running conditions: 95°C 0:20, 95°C 0:01, 60°C 0:20, 45 cycles (values above 40 cycles were defined as not expressed). All genes were run as triplicates, and each run contained the reference gene (PGK1) as internal control, to normalize the expression of the target genes. The qPCR assay identification numbers, TaqMan Gene Exp Assay from Life Technologies/ThermoFisher are listed as follows:

CD28, Hs01007422_m1; CD39, Hs00969556_m1; CD80, Hs01045161_m1; CD244, Hs00175569_m1; EOMES, Hs00172872_m1; IL7R, Hs00902334_m1; KLRG1, Hs00195153_m1; LAG3, Hs00958444_g1; PD1, Hs01550088_m1; PDL1, Hs00204257_m1; PDL2, Hs00228839_m1; PGK1, Hs99999906_m1; TBX21, Hs00894392_m1; TIM3, Hs00958618_m1; VISTA, Hs00735289_m1.

The Δ CT of healthy controls was subtracted from the Δ CT of patients with IMNM to determine the differences ($\Delta\Delta$ CT) and fold change ($2^{-\Delta\Delta$ CT) of gene expression. Gene expression was illustrated by the log10 of fold change values compared to the healthy controls.

Statistical analysis

Kruskal-Wallis one-way analysis of variance followed by Bonferroni-Dunn correction of the post hoc tests was used to analyze quantitative differences of messenger ribonuclein acid (mRNA) transcripts. Data are presented as mean \pm standard error of the mean. The level of significance was set at $p < 0.05$. GraphPad Prism 5.02 software (GraphPad Software, Inc, La Jolla, CA) was used for statistical analysis.

Data availability statement

The authors of this manuscript state that they have carefully documented data, methods, and materials used to conduct the research in the article. Data not provided in the article because

of space limitations can be made available at the request of other investigators for purposes of replicating procedures and results. To our knowledge, there are no legal or ethical reasons or any embargoes on datasets, which may restrict these data availability policy.

Results

Clinical data

For the analysis of exhaustion and senescence markers, we included 12 patients with IMNM (7 male, mean age 47 [18–80]), 7 with sIBM (6 male, mean age 70 [64–75]), 9 with irMyositis (7 male, mean age 71 [56–87]), and 8 healthy controls (6 male, mean age 30 [2–49]) (table).

Of all patients with IMNM, 59% (7 patients) harbored anti-SRP autoantibodies, 41% (5 patients) had anti-HMGCR autoantibodies, and for the patients with sIBM, the autoantibody status for NT5C1A was unknown and not obtainable retrospectively. One patient with ICI-related myositis had anti-Sjögren syndrome–related antigen A autoantibodies. No other MSAs were found in this cohort.


Expression and localization of PD1 and its cognate ligands PD-L1 and PD-L2 in IMNM, sIBM, and irMyositis

We were not able to detect any significant difference between biopsies from SRP- and HMGCR-positive patients with IMNM either by qPCR analyses or by immunohistochemical stains (figure 1). We will, therefore, report all results for both SRP- and HMGCR-positive IMNM as one IMNM phenotype.

In skeletal muscle biopsies of patients with IMNM, CD3⁺ T cells were mostly PD1 positive (figure 2, A and D). Ligand of programmed cell death protein 1 (PD-L1) was only expressed on macrophages in the endomysium, within myophagocytosis, and not on the sarcolemma of myofibers (figure 2B). PD-L1⁺ macrophages did not closely interact with PD1⁺ T cells. The sarcolemma of myofibers was weakly PD-L2⁺, the expression of which is colocalized with major histocompatibility complex (MHC) class I (figure 2, C and G). PD1⁺ T cells are localized adjacent to PD-L2⁺ sarcolemmal structures—thus may form an immunologic synapse (figure 2F). PD-L2 was also expressed on many CD68⁺ macrophages (figure 2E).

In skeletal muscle biopsies of patients with sIBM, numerous CD3⁺ T cells were PD1 positive (figure 2, H and K). PD-L1 was weakly expressed on single macrophages in myophagocytosis or in the endomysium, and not on the sarcolemma of myofibers (figure 2I). PD-L1⁺ macrophages did not show close interaction with PD1⁺ T cells. The sarcolemma of myofibers was PD-L2⁺, the expression of which is intensely colocalized with MHC class I (figure 2, J and N). PD1⁺ T cells only occasionally interacted with PD-L2⁺ sarcolemmal structures (figure 2M). PD-L2 was also expressed on many CD68⁺ macrophages and was co-localized with the sarcolemma of MHC class I⁺ myofibers (figure 2, L and N).

Figure 1 Log10-fold changes of markers of T-cell exhaustion and senescence in samples from patients with IMNM



We did not observe statistically significant differences between patients with anti-SRP and anti-HMGR autoantibodies. Statistical analysis was performed using Kruskal-Wallis one-way analysis of variance with Dunn multiple comparison test. HMGR = hydroxy-3-methylglutaryl-coenzyme A reductase; SRP = signal recognition particle.

In skeletal muscle biopsies of patients with irMyositis, $PD1^+$ T cells were diffusely distributed and frequently clustered close to myofiber necrosis (figure 2O). PD-L1 was strongly positive on many endomysial $CD68^+$ macrophages and in myophagocytic lesions but not on the sarcolemma of myofibers (figure 2, P,R,T). $PD1^+$ T cells only occasionally interacted with $PD-L2^+$ sarcolemmal structures (figure 2T). PD-L2 was strongly positive on the sarcolemma of myofibers and was colocalized with MHC class I (figure 2, Q, S, U).

Molecular expression of exhaustion and senescence markers in IMNM, sIBM, and irMyositis

Consistent with our findings from immunohistochemical stains, expression levels of *PD1* (*PDCD1*), *PDL1* (*CD274*), and *PDL2* (*PDCD1LG2*) in IMNM samples were overall increased by qPCR analyses. Expression levels showed a large variance among individual patients and differences to healthy controls were nonsignificant in statistical analyses. Patients with high expression of *PD1*, however, also showed high expression levels of other markers of T-cell exhaustion and vice versa (figure 3A). The T-cell exhaustion marker *TIM3* was significantly elevated in IMNM samples (compared to healthy controls). We did not find increased expression levels of markers of T-cell senescence in our IMNM samples (figure 3, B and C). Conversely, we observed clear signs of both T-cell senescence and T-cell exhaustion in sIBM samples. mRNA levels for characteristic T-cell exhaustion markers *PD1*, *EOMES*, *TBX21*, *LAG3*, *CD244*,⁸ and *KLRG1* were significantly increased (figure 3, B and C). The PD1 ligand *PDL2* was also significantly increased (figure 3A). Despite significant elevation of *KLRG1* as a marker of T-cell senescence, *CD28* and *CD80* were also significantly elevated in the sIBM samples. *IL7R*, which has been shown to be downregulated in T-cell exhaustion, was significantly upregulated (figure 3C). In irMyositis, we observed 2 distinct subsets of expression pattern. In samples of 2 patients with irMyositis, we found clear signs of T-cell senescence, but not of T-cell exhaustion. In these cases, surface expression of *CD57* on

immunohistochemical stains was high while gene expression of *PD1* and *CD28* were suppressed. These 2 patients had a severe clinical phenotype, leading to death of an associated myocarditis in one case. In all other cases, *CD57* surface expression was undetectable, while *TIM3* and *LAG3* as well as *PDL1* and *PDL2* expression were significantly increased (figure 3, A–C).

Expression of inflammatory markers in sIBM and IMNM


To further characterize the nature and the effect of the observed T-cell subsets in sIBM and IMNM, we investigated markers of inflammation and T-cell activation in muscle biopsies of patients with IMNM and sIBM. In sIBM samples, we found strong upregulation of gene expression of gamma interferon (*IFN γ*), *IL6*, and *IL12*. These markers were also increased in IMNM samples regardless of the antibody subtype (HMGR or SRP) but to a lower degree (figure 4).

Discussion

In this study, we provide systematic evidence of the presence of dysfunctional T cells and activation of the PD1 pathway in IMNM, inclusion body myositis, and immune toxicity-related myopathy. This finding has implications for the understanding of the role of T cells in the pathogenesis of these diseases. States of T-cell exhaustion and senescence have been studied extensively in chronic viral infections and cancer, and are associated with prolonged antigen exposure and subsequent adverse effects on T-cell function.^{9,22,23} The role of T-cell exhaustion and T-cell senescence in autoimmune disease has gathered increased interest in recent years,^{24,25} and co-inhibitory receptors have been shown to play a role in regulating severity of autoimmune disease.²⁶ Despite a heterogeneously used nomenclature, T-cell exhaustion and senescence are actively regulated and, at least in part, reversible T-cell states associated with defective T-cell function.⁸

In this study, we demonstrate that T-cell exhaustion and senescence can be detected in sIBM and IMNM. We were also

Figure 2 Immunohistochemical stains of skeletal muscle biopsies from patients with IMNM, sIBM, or irMyositis




In IMNM biopsies, PD1+ cells are diffusely distributed in the endomysium (A) and most of them correspond to CD3+ T cells (D). Macrophages in myophagocytosis and endomysial macrophages are PD-L1+ (B) but the sarcolemma of myofibers is not (B). CD68+ macrophages coexpress PD-L2 (E), they colocalize with MHC class I+ sarcolemmal membranes (G), and PD1+ lymphocytes interact with PD-L2+ sarcolemmal structures (F) (A and C, original magnification $\times 200$; B, original magnification $\times 400$; D-F, original magnification $\times 600$). In sIBM biopsies, PD1+ cells are CD3+, and they are detectable in the endomysium surrounding myofibers (H, K). PD-L1 is faintly detectable in macrophages within myophagocytosis but not on the sarcolemma and not on endomysial or perimysial macrophages (I). The sarcolemma of myofibers and macrophages are PD-L2+ and colocalize with sarcolemmal MHC class I (J, N). CD68+ macrophages coexpress PD-L2 (L), and PD1+ lymphocytes only occasionally interact with PD-L2+ sarcolemmal structures (M) (H-J, original magnification $\times 200$; K-N, original magnification $\times 600$). In irMyositis, PD1+ cells are detectable in the endomysium and they are CD3+ with variable intensity (O, R). PD-L1 is positive on macrophages but not all CD68+ macrophages express PD-L1 (P). The sarcolemma of myofibers is moderately PD-L2 positive (Q) and faintly coexpresses MHC class I (U). CD68+ macrophages interact with PD-L2+ sarcolemmal structures (S). Single PD1+ T cells interact with PD-L2 sarcolemmal structures (T) (O-Q, original magnification $\times 200$; R-U original magnification $\times 600$). IMNM = immune-mediated necrotizing myopathy; irMyositis = myositis induced by immune checkpoint inhibitors; sIBM = sporadic inclusion body myositis.

able to demonstrate that in irMyositis, T cells with an exhausted phenotype invade the skeletal muscle tissue, and that myofibers upregulate ligands of the inhibitory coreceptor PD1. Upregulation of PD-L1 and PD-L2 has been demonstrated in several autoimmune diseases,^{27–29} and PD-L1/PD-1 and PD-L2/PD-1 interaction has been reported to control the severity of autoimmune disease.²⁹ Furthermore, PD-L1 has been reported to be expressed on muscle fibers in sIBM, polymyositis, and dermatomyositis in vivo and to inhibit T-cell activation in vitro.³⁰ Using double immunohistochemistry/fluorescence, we

were able to detect expression of PD1 ligands PD-L1 on macrophages and PD-L2 on myofibers in sIBM, IMNM, and irMyositis. PD-L2 staining on myofibers was partially overlapping PD1 staining on CD3+ lymphocytes, implicating the formation of so called “immunologic synapses” and a potential role of PD-L2/PD1 interaction in modulating T-cell activation.³¹ These findings were also reflected by significantly increased *PDL2* mRNA levels in sIBM and irMyositis and increased *PDL1* mRNA levels in irMyositis. *PDL1* and *PDL2* expression have been shown to be driven by *IFN* γ .³¹

Figure 3 Markers of T-cell exhaustion and senescence in patient skeletal muscle samples



mRNA levels of genes related to T-cell exhaustion (A and B) and T-cell senescence (C) from IMNM (n = 12), sIBM (n = 7), and irMyositis (n = 9) samples. Statistical analysis was performed using Kruskal-Wallis one-way analysis of variance with Dunn multiple comparison test. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ —difference between displayed groups in log fold changes. # $p < 0.05$; ## $p < 0.01$; ### $p < 0.001$ —differences between dCT of patient groups and normal control. IMNM = immune-mediated necrotizing myopathy; irMyositis = myositis induced by immune checkpoint inhibitors; sIBM = sporadic inclusion body myositis.


Consistent with this report, *IFN γ* mRNA levels were significantly elevated in sIBM and IMNM samples compared to control, with significantly higher levels in sIBM than in muscle tissues of IMNM cases. *IFN γ* is a key regulatory molecule of cytotoxic T cells (CTLs),^{32,33} and CTLs have been reported to invade skeletal muscle in sIBM and to a much lesser degree also in IMNM.^{1,34} Thus far, there are no studies on the role of T cells in irMyositis in the literature. In this study, we now provided evidence that a subset of the invading T cells exhibit markers of severe T-cell exhaustion in sIBM, IMNM, and irMyositis.

Using immunohistochemistry and mRNA qPCR, we were able to detect high levels of gene expression for *PD1* and several other inhibitory coreceptors (*KLRG1*, *LAG3*, *TIM3*, *EOMES*, *TBET*) associated with a severely exhausted phenotype²³ in sIBM skeletal muscle samples. In qPCR analysis of IMNM skeletal muscle biopsies, *TIM3* mRNA levels were significantly increased. *TIM3* is an important marker for T-cell exhaustion⁸ and is a negative regulator of T-cell activation in infections^{35,36} and cancer.³⁷ In addition, *TIM-3* is a key modulator of T-cell activation and disease severity in autoimmune disease.^{26,38} T-cell exhaustion predicts favorable outcome in several immune-mediated diseases.²⁵ Correlating

clinical outcome with expression levels of exhaustion markers was beyond the scope of this study, but might explain in parts the heterogeneous findings in this group. Hence, we demonstrate that T cells in skeletal muscles of patients with IMNM can show an “exhausted” phenotype, which might be the consequence of prolonged exposure of these cells to high levels of autoantigen. Levels of autoantigens in sera of IMNM patients are actually directly associated with disease activity and creatine kinase levels.³ This also indirectly fosters the hypothesis that anti-SRP and anti-HMGCR autoantibodies play decisive roles in IMNM.¹ We did not find any significant difference in expression levels between anti-HMGCR⁺ and anti-SRP⁺ IMNM, and interindividual variance was high among IMNM samples.

Expression of *PD1* and other markers for T-cell exhaustion and T-cell senescence in tumor infiltrating T cells, as well as the expression of *PD1* ligands on tumor cells have been well studied in several cancers. Inducing and maintaining T-cell inhibition through activation of inhibitory molecules on tumor-specific T cells have been implicated as one of the driving mechanisms for tumor immune escape.²³ Blocking these inhibitory signals leads to robust beneficial anticancer immune responses.^{39,40} In this study, we provide the first evidence that T cells in irMyositis acquire an exhausted

Figure 4 Markers of inflammation in IMNM (n = 42) and sIBM (n = 7) skeletal muscle samples



Markers for interstitial inflammation were upregulated in samples of IMNM and sIBM. All changes were significant at $p < 0.01$ compared to control samples (n = 8). TNFa and INFg levels differed significantly between IMNM and sIBM samples. Statistical analysis was performed using Kruskal-Wallis one-way analysis of variance with Dunn multiple comparison test. * $p < 0.05$ —difference between displayed groups in log fold changes. IMNM = immune-mediated necrotizing myopathy; sIBM = sporadic inclusion body myositis.

phenotype with high expression of PD-1, LAG-3, and TIM-3, reflecting a similar pattern found on tumor infiltrating T cells.²³ Interestingly, in 2 severe cases of irMyositis with associated immune myocarditis, we observed no signs of T-cell exhaustion in our samples but distinct markers of T-cell senescence. These samples exhibited high surface expression levels of CD57 and low expression of CD28 and PD1.⁴¹ There was no association with the delay from symptom onset to biopsy or specific immunosuppressive treatment before biopsy. Further studies with larger sample sizes are needed to confirm the association of symptom severity and T-cell senescence. Differences in the distribution of weakness and frequency of a concomitant autoimmune myocarditis between cases showing predominantly T-cell exhaustion or T-cell senescence would be of particular interest. Consistent with previous reports addressing CD57 expression on invading T cells in sIBM,¹⁷ we also found CD57 expression in samples of sIBM. Furthermore, expression levels of KLRG1 and CD244 were significantly increased in sIBM samples as markers of exhaustion as well as T cell differentiation.^{12,23} However, IL7R, a receptor typically downregulated in exhausted T cells and involved in a sustained effective T-cell response,⁸ was also significantly upregulated in our sIBM samples. These findings suggest a heterogeneous composition of senescent, exhausted, as well as differentiated cytotoxic invading T cells in sIBM. Analyzing T-cell subsets in the peripheral blood and muscle infiltrates of sIBM patients has previously revealed an oligoclonal expansion of CD8⁺ T cells and a deficiency of regulatory T cells,⁴² and the PDL1-PD1 axis has been shown to convert Th1 cells into T regs.⁴³ Our finding of pronounced T-cell exhaustion and senescence in sIBM samples corroborates the notion of sIBM as a primarily inflammatory myopathy.

In this study, we report retrospective analyses of skeletal muscle biopsies with confirmed sIBM, IMNM, and irMyositis. We were therefore unable to analyze expression patterns on a single-cell level to further disentangle different invading T cell subsets, which might lead to a misinterpretation of the prevailing T-cell population. Nevertheless, in this study, we present clear evidence of T-cell exhaustion, and T-cell senescence to varying degrees in all 3 studied myositis entities: In IMNM samples, we found evidence of exhaustion, but no signs of senescence. Clearer signs of T-cell exhaustion were visible in irMyositis with a subset of patients showing markers of T-cell senescence, but not of exhaustion. In sIBM, we found high expression of markers for T-cell exhaustion and T-cell senescence. Differences in the duration of disease might interfere with the immune phenotype of the entities studied herein. Taken together, our findings implicate the involvement of muscle-specific T cells with specific phenotypes in the development of sIBM, IMNM, and irMyositis. Activation of coinhibitory receptors could therefore be a viable treatment target in sporadic immune-mediated myositis entities mandating further prospective studies correlating markers of T-cell exhaustion with clinical outcome.

Authors contributions

S. Knauss, C. Preusse, W. Stenzel, H. Radbruch, R. Mothes: study concept and design, acquisition, analysis and interpretation of data. Y. Allenbach, S. Leonard-Louis, M. Touat, N. Fischer, V. Matyash, W. Böhrerle, M. Endres, H.-H. Goebel, O. Benveniste: analysis and interpretation of data.

Study funding

Deutsche Gesellschaft für Muskelkranke e.V. (DGM) to W. Stenzel.

Disclosure

S. Knauss, C. Preusse, Y. Allenbach, and S. Leonard-Louis report no disclosures. M. Touat served on the scientific advisory board for Agios, Taiho Oncology, received travel funding from Agios, Merck Sharp and Dohme, received research support from Fondation pour la Recherche Medicale. N. Fischer reports no disclosures. H. Radbruch received travel funding and/or speaker honoraria from Novartis, Sanofi, received research support from Novartis, Sanofi, Deutsche Forschungsgemeinschaft. R. Mothes and V. Matyash report no disclosures. W. Böhrerle received speaker honoraria from NOGGO e.V., BMS, received research support from NeuroCure, QUEST. M. Endres served on the scientific advisory board for Center of Stroke Research Berlin, Boehringer Ingelheim, Bayer, Amgen, Covidien, received speaker honoraria paid to institution from Boehringer Ingelheim, Pfizer, Sanofi, Bayer, BMS, GSK, Amgen, Novartis, served on the editorial board for *Stroke*, *Journal of Molecular Medicine*, *Neuropsychopharmacology*, *Aktuelle Neurologie*, *Journal of the European Stroke Organization*, has been employed by German Center for Neurodegenerative Diseases, received research support from Roche, Bayer, German Ministry of Education and Science, Deutsche Forschungsgemeinschaft, European

Union, German Center for Cardiovascular Research, German Center for Neurodegenerative Diseases, Berlin Institute of Health, VolkswagenFoundatoin, CoronaFoundation, Fondation Leducq Transatlantic Network. H.-H. Goebel served on the editorial board for *Neuromuscular Disorders*, *Neuropathology and Applied Neurobiology*, *Bran Pathology*, *Clinical Neuropathology*. C. Benveniste served on the scientific advisory board for Csl Behring, Novartis, LFB, received travel funding from CSL Behring, LFB, consulted for Novartis, CSL Behring, Neovacs, received research support from LFB, Novartis, Shire, CSL Behring, Neovacs, DGOS/INSERM, PHRC, AFM, They Myositis Association. W. Stenzel served on the editorial board for *Neuromuscular Disorders*, *Neuropathology and Applied Neurobiology*. Disclosures available: Neurology.org/NN.

Publication history

Received by *Neurology: Neuroimmunology & Neuroinflammation* September 7, 2018. Accepted in final form January 23, 2019.

References

- Allenbach Y, Arouche-Delaperche L, Preusse C, et al. Necrosis in anti-SRP-and anti-HMGCR-myopathies: role of autoantibodies and complement. *Neurology* 2018;90:e507–e517.
- Arouche-Delaperche L, Allenbach Y, Amelin D, et al. Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. *Ann Neurol* 2017;81:538–548.
- Allenbach Y, Drouot L, Rigolet A, et al. Anti-hmcr autoantibodies in European patients with autoimmune necrotizing myopathies. *Medicine* 2014;93:150–157.
- Cherin P, Herson S, Crevon MC, et al. Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis. *J Rheumatol* 1996;23:1135–1142.
- Benjamin Larman H, Salajegheh M, Nazareno R, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. *Ann Neurol* 2013;73:408–418.
- Pluk H, van Hoeve BJ, van Dooren SHJ, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. *Ann Neurol* 2013;73:397–407.
- Goyal NA, Cash TM, Alam U, et al. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. *J Neurol Neurosurg Psychiatr* 2016;87:373–378.
- Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. *Nat Rev Immunol* 2015;15:486–499.
- Wherry EJ. T cell exhaustion. *Nat Immunol* 2011;12:492–499.
- Duraiswamy J, Ibegbu CC, Masopust D, et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. *J Immunol* 2011;186:4200–4212.
- Hong JJ, Amancha PK, Rogers K, Ansari AA, Villingier F. Re-evaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection. *PLoS One*; 2013;8:e60186.
- Legat A, Speiser DE, Pircher H, Zehn D, Fuentes Marraco SA. Inhibitory receptor expression depends more dominantly on differentiation and activation than "exhaustion" of human CD8 T cells. *Front Immunol* 2013;4:455.
- Wei SC, Levine JH, Cogdill AP, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. *Cell* 2017;170:1120–1133.e17.
- Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. *JAMA Neurol* 2017;74:1216–1217.
- Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. *Trends Immunol* 2014;35:51–60.
- Akbar AN, Henson SM. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? *Nat Rev Immunol* 2011;11:289–295.
- Greenberg SA, Pinkus JL, Amato AA, Kristensen T, Dorfman DM. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. *Brain* 2016;139:1348–1360.
- Allenbach Y, Mammen AL, Stenzel W, Benveniste O. Immune-Mediated Necrotizing Myopathies Working G. 224th ENMC International Workshop: clinico-seropathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. *Neuromuscul Disord* 2017;28:87–99.
- Rose MR; ENMC IBM Working Group. 188th ENMC International Workshop: inclusion body myositis, 2–4 December 2011, Naarden, The Netherlands. *Neuromuscul Disord* 2013;23:1044–1055.
- Touat M, Maissonobe T, Knauss S, et al. Immune checkpoint Inhibitor-related myositis and myocarditis in patients with cancer. *Neurology* 2018;91:e985–e994.
- Preusse C, Allenbach Y, Hoffmann O, et al. Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis. *Acta Neuropathologica Commun* 2016;4:1–12.
- Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. *J Exp Med* 1998;188:2205–2213.
- Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. *Curr Opin Immunol* 2013;25:214–221.
- McKinney EF, Smith KG. T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases. *Immunol Cell Biol* 2016;94:935–942.
- McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. *Nature* 2015;523:612–616.
- Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. *Nat News* 2002;415:536–541.
- Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. *Eur J Immunol* 2003;33:2706–2716.
- Mataki N, Kikuchi K, Kawai T, et al. Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases. *Am J Gastroenterol* 2007;102:302–312.
- Menke J, Lucas JA, Zeller GC, et al. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. *J Immunol* 2007;179:7466–7477.
- Wiendl H, Mitsdoerffer M, Schneider D, et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. *FASEB J* 2003;17:1892–1894.
- Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. *Nat Immunol* 2001;2:261–268.
- Ghanekar SA, Nomura LE, Suni MA, Picker LJ, Maecker HT, Maino VC. Gamma interferon expression in CD8(+) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. *Clin Diagn Lab Immunol* 2001;8:628–631.
- Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. *Adv Immunol* 2007;96:41–101.
- Preuß C, Goebel HH, Held J, et al. Immune-mediated necrotizing myopathy is characterized by a specific Th1-m1 polarized immune profile. *Am J Pathol* 2012;120:12161–12171.
- Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. *J Exp Med* 2008;205:2763–2779.
- Jin HT, Anderson AC, Tan WG, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. *Proc Natl Acad Sci USA* 2010;107:14733–14738.
- Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8 + T cell dysfunction in melanoma patients. *J Exp Med* 2010;207:2175–2186.
- Rangachari M, Zhu C, Sakuishi K, et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. *Nat Med* 2012;18:1394–1400.
- Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. The expanding role of immunotherapy. *Cancer Treat Rev* 2017;54:74–86.
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012;12:252–264.
- Brenchley JM. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. *Blood* 2002;101:2711–2720.
- Benveniste O, Stenzel W, Hilton-Jones D, Sandri M, Boyer O, van Engelen BGM. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. *Acta Neuropathol* 2015;129:611–624.
- Amarnath S, Mangus CW, Wang JC, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. *Sci Transl Med* 2011;3:111ra120.

Neurology® Neuroimmunology & Neuroinflammation

PD1 pathway in immune-mediated myopathies: Pathogenesis of dysfunctional T cells revisited

Samuel Knauss, Corinna Preusse, Yves Allenbach, et al.
Neurol Neuroimmunol Neuroinflamm 2019;6;
DOI 10.1212/NXI.0000000000000558

This information is current as of April 10, 2019

Updated Information & Services	including high resolution figures, can be found at: http://nn.neurology.org/content/6/3/e558.full.html
References	This article cites 43 articles, 8 of which you can access for free at: http://nn.neurology.org/content/6/3/e558.full.html##ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Immunology http://nn.neurology.org/cgi/collection/all_immunology All Neuromuscular Disease http://nn.neurology.org/cgi/collection/all_neuromuscular_disease Chemotherapy-tumor http://nn.neurology.org/cgi/collection/chemotherapytumor
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://nn.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.

